The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications

Gregory Dean, Stephen Hanauer, Josh Levitsky – 11 May 2020 – The pathogenesis of primary sclerosing cholangitis (PSC), a progressive biliary tract disease without approved medical therapy, is not well understood. The relationship between PSC and inflammatory bowel disease has inspired theories that intestinal factors may contribute to the development and progression of hepatobiliary fibrosis in PSC. There is evidence from both fecal and mucosa‐associated microbial studies that patients with PSC harbor an abnormal enteric microbiome.

The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications

Gregory Dean, Stephen Hanauer, Josh Levitsky – 11 May 2020 – The pathogenesis of primary sclerosing cholangitis (PSC), a progressive biliary tract disease without approved medical therapy, is not well understood. The relationship between PSC and inflammatory bowel disease has inspired theories that intestinal factors may contribute to the development and progression of hepatobiliary fibrosis in PSC. There is evidence from both fecal and mucosa‐associated microbial studies that patients with PSC harbor an abnormal enteric microbiome.

Left Hepatic Vein Preferential Approach Based on Anatomy Is Safe and Feasible for Laparoscopic Living Donor Left Lateral Sectionectomy

Lu Lu, Zheng‐Xin Wang, Wen‐Wei Zhu, Cong‐Huan Shen, Yi‐Feng Tao, Zhen‐Yu Ma, Quan‐Bao Zhang, Rui‐Dong Li, Hu‐Liang Jia, Lun‐Xiu Qin, Jin‐Hong Chen – 11 May 2020 – We assess the safety and feasibility of the left hepatic vein preferential approach (LHVPA) based on left hepatic vein (LHV) anatomy for living donor laparoscopic left lateral sectionectomy (LLLS). Data from 50 donors who underwent LLLS in Huashan Hospital from October 2016 to November 2019 were analyzed retrospectively.

Evolution of Systemic Therapy for Hepatocellular Carcinoma

Richard S. Finn, Andrew X. Zhu – 7 May 2020 – Despite being one of the leading causes of cancer death globally, hepatocellular carcinoma (HCC) has historically not been the focus of novel drug development. That has changed in the past several years, with the results from a number of hallmark phase 3 studies in advanced HCC. In HCC, immune‐oncology approaches have garnered much attention; there is still a need to better understand criteria for patient selection and to optimize combination strategies to maximize the potential of these approaches.

Subscribe to